Details of therapy.
| Drugs | Week 0 | Week 12 | |||
|---|---|---|---|---|---|
| N (%) | Median (IQR) | N(%) | No. of Patients | Median (IQR) | |
| Prednisolone | 7 (25) | 5 mg/day (5–15) | 6 (21.4) | –1 | 10 mg/day (5–20) |
| Methotrexate | 4 (14.2) | 15 mg/week (11.25–16.8) | 21 (75) | +14 | 12.5 mg/week (10–15) |
| Sulfasalazine | 7 (25) | 1 g/day (1–1.5) | 7 (25) | 0 | 1 g/day (1–1.5) |
| Hydroxychloroquine | 2 (7) | 300 mg/day (200–400) | 1 (3.5) | –1 | 200 mg/day |
| Leflunomide | 2 (7) | 15 mg/day (10–20) | 3 (10.7) | +1 | 20 mg/day (10–20) |
| Infliximab | 0 | 2 (7) | +2 | 3 mg/kg | |
| Ocrelizumab | 0 | 3 (10.7) | +3 | 200 mg fortnightly × 1 | |
| Single DMARD | 5 | 17 | |||
| Double DMARD | 3 | 11 | |||
| Triple DMARD | 1 | 0 | |||
DMARD: disease-modifying antirheumatic drug.
* At baseline and then 2 weeks later.